Nevro (NVRO) Q4 2024 earnings summary

Executive summary

• Fourth-quarter 2024 worldwide revenue was $105.5M, down 9.1% year-over-year; full-year 2024 revenue was $408.5M, down 3.9% from 2023.

• Adjusted EBITDA for full-year 2024 improved to negative $13.6M from negative $17.7M in 2023, exceeding revised expectations.

• Announced definitive agreement for acquisition by Globus Medical in an all-cash deal valued at ~$250M, expected to close in Q2 2025.

• Launched HFX iQ SCS system with AdaptivAI in the US and select European countries following CE Mark certification.

• Published new clinical data supporting efficacy of 10 kHz SCS therapy and SI Joint Fusion System.

Financial highlights

• Q4 2024 U.S. revenue was $91.4M, down 9.9% year-over-year; international revenue was $14.1M, down 3.8%.

• Gross margin for Q4 2024 was 62.5%, down from 70.1% in Q4 2023; full-year 2024 gross margin was 66.0%, down from 68.2%.

• Q4 2024 net loss from operations was $51.4M (or $24.1M excluding one-time items); full-year net loss from operations was $126.2M.

• Cash, cash equivalents, and short-term investments totaled $292.5M as of December 31, 2024, up $15.5M sequentially.

• Adjusted EBITDA for Q4 2024 was negative $5.2M, compared to positive $8.4M in Q4 2023.

Outlook and guidance

• No full-year 2025 guidance issued due to pending acquisition by Globus Medical; no earnings call or webcast held for Q4 and full-year 2024 results.